| |
Odds ratio (95% confidence interval)
|
|---|
|
DM
|
Non-DM
|
|---|
|
Total
|
HTN
|
GN
|
PKD
|
|---|
|
Crude
|
0.964 (0.943–0.984)
|
0.951 (0.935–0.967)
|
0.941 (0.912–0.971)
|
0.955 (0.931–0.979)
|
0.944 (0.904–0.987)
|
|
Model 1
|
0.973 (0.949–0.997)
|
0.969 (0.951–0.988)
|
0.949 (0.916–0.984)
|
0.980 (0.952–1.009)
|
0.954 (0.907–1.004)
|
|
Model 2
|
0.952 (0.923–0.981)
|
0.957 (0.935–0.980)
|
0.944 (0.905–0.985)
|
0.949 (0.913–0.987)
|
0.962 (0.911–1.016)
|
|
Model 3
|
0.946 (0.913–0.980)
|
0.957 (0.932–0.983)
|
0.950 (0.901–1.003)
|
0.942 (0.900–0.986)
|
0.950 (0.899–1.004)
|
|
Model 4
|
0.933 (0.898–0.970)
|
0.959 (0.932–0.986)
|
0.939 (0.885–0.996)
|
0.942 (0.896–0.990)
|
0.969 (0.913–1.028)
|
- Adiponectin 1 μg/mL increase, subgroup analysis was performed according to the cause of chronic kidney disease
- Model 1: adjusted for age, gender, smoking status, and body mass index
- Model 2: adjusted for model 1 + hemoglobin, serum albumin, uric acid, phosphate, and parathyroid hormone
- Model 3: adjusted for model 2 + hs-CRP, urine albumin-to-creatinine ratio, and eGFR
- Model 4: adjusted for model 3 + coronary artery disease, cerebrovascular disease, ARB, diuretics, statin, ezetimibe, and fibrate
-
DM diabetic mellitus, HTN hypertension, GN glomerulonephritis, PKD polycystic kidney disease, hs-CRP high sensitivity C-reactive protein, eGFR estimated glomerular filtration rate, ARB angiotensin II receptor blocker
